BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24940339)

  • 1. Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis.
    Ngala RA; Fianko K
    Afr Health Sci; 2013 Dec; 13(4):1107-16. PubMed ID: 24940339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.
    Muhammad S; Sani MU; Okeahialam BN
    Ann Afr Med; 2013; 12(1):24-8. PubMed ID: 23480991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients.
    Manuthu EM; Joshi MD; Lule GN; Karari E
    East Afr Med J; 2008 Jan; 85(1):10-7. PubMed ID: 18543521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
    Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
    HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study.
    Abebe M; Kinde S; Belay G; Gebreegziabxier A; Challa F; Gebeyehu T; Nigussie P; Tegbaru B
    BMC Res Notes; 2014 Jun; 7():380. PubMed ID: 24950924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
    Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
    Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
    Koppel K; Bratt G; Eriksson M; Sandström E
    Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe dyslipidemia and immune activation in HIV patients with dysglycemia.
    Jin C; Ji S; Xie T; Höxtermann S; Fuchs W; Lu X; Wu H; Cheng L; Skaletz-Rorowski A; Brockmeyer NH; Wu N
    HIV Clin Trials; 2016 Sep; 17(5):189-96. PubMed ID: 27409415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
    Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
    BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia.
    Tesfaye DY; Kinde S; Medhin G; Megerssa YC; Tadewos A; Tadesse E; Shimelis T
    Diabetes Metab Syndr; 2014; 8(2):102-7. PubMed ID: 24907175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haptoglobin phenotypes with weak antioxidant capacity increase risk factors of cardiovascular disease in Ghanaian HIV-infected patients on highly active antiretroviral therapy.
    Tagoe EA; Tagoe INA; Kuleape JA; Puplampu P; Amanquah S; Asare-Anane H; Quaye O
    Trop Med Int Health; 2019 Jun; 24(6):766-774. PubMed ID: 30851231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid peroxidation and total cholesterol in HAART-naïve patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon.
    Teto G; Kanmogne GD; Torimiro JN; Alemnji G; Nguemaim FN; Takou D; Nanfack A; Tazoacha A
    PLoS One; 2013; 8(6):e65126. PubMed ID: 23762297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
    Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
    AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.